Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis

• DOI: 10.1016/j.metabol.2023.155612
• Publication Date: 2023-06-03T23:05:48Z
• Authors: Hye Jin Chun; Eun Ran Kim; Minyoung Lee; Da Hyun Choi; Soo Hyun Kim; Eugene Shin; Jin-Hong Kim; Jin Won Cho; Dai Hoon Han; Bong-Soo Cha; Yong-ho Lee
• Keywords: 610; Inbred C57BL; Diet, High-Fat; Sodium-Glucose Transporter 2 Inhibitors* / pharmacology; Mice; Liver / metabolism; Sodium-glucose transport protein 2; Sodium-Glucose Transporter 2; Non-alcoholic Fatty Liver Disease; O-linked N-acetylglucosamine; Autophagy; Animals; Humans; Hepatocytes / metabolism; Sodium-Glucose Transporter 2 Inhibitors; Non-alcoholic steatohepatitis; Glucose / metabolism; Sodium-Glucose Transporter 2 / metabolism; Animal; Diabetes; Sodium; Non-alcoholic Fatty Liver Disease* / metabolism; Lipids; Diet; 620; Mice, Inbred C57BL; High-Fat; Disease Models, Animal; Glucose; Liver; Disease Models; Hepatocytes

Steatosis reducing effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in non-alcoholic steatohepatitis (NASH) has been consistently reported in humans, but their mechanism remains uncertain. In this study, we examined the expression of SGLT2 in human livers and investigated the crosstalk between SGLT2 inhibition and hepatic glucose uptake, intracellular O-GlcNAcylation, and autophagic regulation in NASH.Human liver samples obtained from subjects with/without NASH were analyzed. For in vitro studies, human normal hepatocytes and hepatoma cells were treated with SGLT2 inhibitor under high-glucose and high-lipid conditions. NASH in vivo was induced by a high-fat, -fructose, and -cholesterol Amylin liver NASH (AMLN) diet for 10 weeks followed by an additional 10 weeks with/without SGLT2 inhibitor (empagliflozin 10 mg/kg/day).Liver samples from subjects with NASH were associated with increased SGLT2 and O-GlcNAcylation expression compared with controls. Under NASH condition (in vitro condition with high glucose and lipid), intracellular O-GlcNAcylation and inflammatory markers were increased in hepatocytes and SGLT2 expression was upregulated; SGLT2 inhibitor treatment blocked these changes by directly reducing hepatocellular glucose uptake. In addition, decreased intracellular O-GlcNAcylation by SGLT2 inhibitor promoted autophagic flux through AMPK-TFEB activation. In the AMLN diet-induced NASH mice model, SGLT2 inhibitor alleviated lipid accumulation, inflammation, and fibrosis through autophagy activation related to decreased SGLT2 expression and O-GlcNAcylation in the liver.This study firstly demonstrates increased SGLT2 expression in NASH and secondly reveals the novel effect of SGLT2 inhibition on NASH through autophagy activation mediated by inhibition of hepatocellular glucose uptake and consequently decreased intracellular O-GlcNAcylation.